Table 3.
Western countries (n = 244) |
East Asia (n = 266) |
|||||
---|---|---|---|---|---|---|
Gastritis n = 98 |
DU n = 97 |
Cancer n = 49 |
Gastritis n = 86 |
DU n = 90 |
Cancer n = 90 |
|
BabA-H | 75 (77%) | 85 (88%) | 41 (84%) | 81 (94%) | 80 (89%) | 78 (93%) |
BabA-L | 4 (4.1%) | 9 (9.3%) | 6 (12%) | 5 (5.8%) | 10 (11%) | 12 (13%) |
BabA negative | 19 (19%) | 3 (3.1%)a | 2 (4.1%)b | 0 | 0 | 0 |
cagA positive | 77 (79%) | 85 (88%) | 43 (88%) | 82 (95%) | 90 (100%) | 88 (98%) |
vacA s1 | 76 (78%) | 88 (91%)b | 43 (88%) | 86 (100%) | 90 (100%) | 90 (100%) |
cagA positive, s1, BabA-H | 72 (73%) | 76 (78%) | 37 (76%) | 77 (90%) | 80 (89%) | 76 (84%) |
cagA positive, s1, BabA-L | 3 (3.1%) | 8 (8.2%) | 4 (8.2%) | 5 (5.8%) | 10 (11%) | 12 (13%) |
cagA negative, s2, BabA negative | 18 (18%) | 3 (3.1%)c | 2 (4.1%)b | 0 | 0 | 0 |
Other types | 5 (5.1%) | 10 (10%) | 6 (12%) | 4 (4.7%) | 0 | 2 (2.2%) |
NOTE. Six samples from Western countries and 4 from East Asia had borderline results for BabA and were excluded. The P value was determined by the χ2 test.
P < .001 compared with gastritis.
P < .05 compared with gastritis.
P < .01 compared with gastritis.